• Something wrong with this record ?

Effect of co-milling on dissolution rate of poorly soluble drugs

M. Slámová, K. Prausová, J. Epikaridisová, J. Brokešová, M. Kuentz, J. Patera, P. Zámostný

. 2021 ; 597 (-) : 120312. [pub] 20210201

Language English Country Netherlands

Document type Journal Article

Co-milling of a drug with a co-former is an efficient technique to improve the solubility of drugs. Besides the particle size reduction, the co-milling process induces a structural disorder and the creation of amorphous regions. The extent of drug solubility enhancement is dependent on the proper choice of co-milling co-former. The aim of this work was to compare the effects of different co-formers (meglumine and polyvinylpyrrolidone) on the dissolution rates of glass forming (indomethacin) and non-glass forming (mefenamic acid) model drugs. A positive impact of the co-milling on the dissolution behavior was observed in all co-milled mixtures, even if no substantial amorphization was observed. While meglumine exhibited pronounced effects on the dissolution rate of both drugs, the slightest enhancement was observed in mixtures with polyvinylpyrrolidone. The evaluation of specific release rate revealed the surface activation of drug particle is responsible for improving the dissolution rate of both drug types, but for the glass former, this surface activation could be persistent while maintaining a high dissolution rate even until a high fraction of drug is released. Our results, therefore, indicate that adequate co-former choice and consideration of drug glass forming ability are important for a successful co-milling approach to poorly water-soluble drugs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019043
003      
CZ-PrNML
005      
20210830100620.0
007      
ta
008      
210728s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijpharm.2021.120312 $2 doi
035    __
$a (PubMed)33540023
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Slámová, Michaela $u Department of Organic Technology, UCT Prague, Technická 5, 166 28 Prague 6, Dejvice, Czech Republic. Electronic address: slamovam@vscht.cz
245    10
$a Effect of co-milling on dissolution rate of poorly soluble drugs / $c M. Slámová, K. Prausová, J. Epikaridisová, J. Brokešová, M. Kuentz, J. Patera, P. Zámostný
520    9_
$a Co-milling of a drug with a co-former is an efficient technique to improve the solubility of drugs. Besides the particle size reduction, the co-milling process induces a structural disorder and the creation of amorphous regions. The extent of drug solubility enhancement is dependent on the proper choice of co-milling co-former. The aim of this work was to compare the effects of different co-formers (meglumine and polyvinylpyrrolidone) on the dissolution rates of glass forming (indomethacin) and non-glass forming (mefenamic acid) model drugs. A positive impact of the co-milling on the dissolution behavior was observed in all co-milled mixtures, even if no substantial amorphization was observed. While meglumine exhibited pronounced effects on the dissolution rate of both drugs, the slightest enhancement was observed in mixtures with polyvinylpyrrolidone. The evaluation of specific release rate revealed the surface activation of drug particle is responsible for improving the dissolution rate of both drug types, but for the glass former, this surface activation could be persistent while maintaining a high dissolution rate even until a high fraction of drug is released. Our results, therefore, indicate that adequate co-former choice and consideration of drug glass forming ability are important for a successful co-milling approach to poorly water-soluble drugs.
650    _2
$a příprava léků $7 D004339
650    _2
$a indomethacin $7 D007213
650    _2
$a velikost částic $7 D010316
650    12
$a léčivé přípravky $7 D004364
650    12
$a povidon $7 D011205
650    _2
$a rozpustnost $7 D012995
655    _2
$a časopisecké články $7 D016428
700    1_
$a Prausová, Kateřina $u Department of Organic Technology, UCT Prague, Technická 5, 166 28 Prague 6, Dejvice, Czech Republic
700    1_
$a Epikaridisová, Julie $u Department of Organic Technology, UCT Prague, Technická 5, 166 28 Prague 6, Dejvice, Czech Republic
700    1_
$a Brokešová, Jana $u Faculty of Pharmacy, Department of Pharmaceutical Technology, Charles University, Ak. Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
700    1_
$a Kuentz, Martin $u University of Applied Sciences and Arts Northwestern Switzerland, Institute of Pharmaceutical Technology, Gründenstr. 40, CH-4132 Muttenz, Switzerland
700    1_
$a Patera, Jan $u Department of Organic Technology, UCT Prague, Technická 5, 166 28 Prague 6, Dejvice, Czech Republic
700    1_
$a Zámostný, Petr $u Department of Organic Technology, UCT Prague, Technická 5, 166 28 Prague 6, Dejvice, Czech Republic
773    0_
$w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 597, č. - (2021), s. 120312
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33540023 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100620 $b ABA008
999    __
$a ok $b bmc $g 1689968 $s 1139489
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 597 $c - $d 120312 $e 20210201 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...